Cargando…

Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis

As myocardial fibrosis might be an important contributor to the association of diabetes mellitus with left ventricular (LV) dysfunction and chronic heart failure (HF), we investigated the profile of some proinflammatory, profibrotic biomarkers in patients with type 2 diabetes mellitus (T2DM) at vari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebedev, D. A., Lyasnikova, E. A., Vasilyeva, E. Yu, Babenko, A. Yu, Shlyakhto, E. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669344/ https://www.ncbi.nlm.nih.gov/pubmed/33224989 http://dx.doi.org/10.1155/2020/6976153

Ejemplares similares

Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Lakhani, Ishan, et al.
Publicado: (2019)

Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus
por: Lebedev, Denis A., et al.
Publicado: (2021)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction
por: Nadruz, Wilson, et al.
Publicado: (2017)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Kitai, Takeshi, et al.
Publicado: (2020)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature
por: Hu, Yang, et al.
Publicado: (2018)

Ventricular arrhythmias not meeting criteria for terminating cardiopulmonary exercise testing stratify prognosis and disease severity in heart failure of preserved, midrange, and reduced ejection fraction
por: Popovic, Dejana, et al.
Publicado: (2020)

Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients
por: Ye, Fanhao, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction
por: Hanff, Thomas C., et al.
Publicado: (2021)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
por: Sweeney, Mark, et al.
Publicado: (2020)

Racial differences of heart failure with midrange ejection fraction (HFmrEF): a large urban centre-based retrospective cohort study in the USA
por: Li, Dan Leslie, et al.
Publicado: (2019)

Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
por: Dhore-patil, Aneesh, et al.
Publicado: (2022)

Left Ventricular Remodeling Risk Predicted by Two-Dimensional Speckle Tracking Echocardiography in Acute Myocardial Infarction Patients with Midrange or Preserved Ejection Fraction in Western Romania
por: Bordejevic, Diana Aurora, et al.
Publicado: (2021)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Strategies for management of heart failure with preserved ejection fraction
por: Winchester, David E.
Publicado: (2019)

Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report
por: Narang, Nikhil, et al.
Publicado: (2017)

Surgical treatment of patients with aortic valve disease complicated with moderate functional mitral regurgitation and heart failure with midrange ejection fraction: a cohort study
por: Zhao, Wei, et al.
Publicado: (2022)

Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2017)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022)

Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction
por: Liu, Xiao, et al.
Publicado: (2022)

Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction
por: Kirkman, Danielle L., et al.
Publicado: (2020)

The Gut Microbiome of Heart Failure With Preserved Ejection Fraction
por: Beale, Anna L., et al.
Publicado: (2021)

Effects of Kangdaxin on myocardial fibrosis in heart failure with preserved ejection fraction rats
por: Wu, Xiang, et al.
Publicado: (2022)

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
por: Ejiri, Kentaro, et al.
Publicado: (2020)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension
por: Patel, Ravi B., et al.
Publicado: (2020)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries
por: Choi, Ki Hong, et al.
Publicado: (2018)

Cell Therapy for Heart Failure With Preserved Ejection Fraction
por: Borlaug, Barry A., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction
por: Lewis, Gavin A., et al.
Publicado: (2022)

Animal models of heart failure with preserved ejection fraction
por: Conceição, G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p89r1daapui54od6pj5s2bdjgc